Akorn Provides Preliminary Second Quarter 2019 Results
August 01, 2019 07:00 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second...
Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
July 11, 2019 16:32 ET
|
Akorn, Inc.
LAKE FOREST, Ill., July 11, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before...
Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
June 28, 2019 07:00 ET
|
Akorn, Inc.
LAKE FOREST, Ill., June 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic...
Akorn Receives FDA Warning Letter
June 25, 2019 07:35 ET
|
Akorn, Inc.
LAKE FOREST, Ill., June 25, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food...
Akorn to Present at the Jefferies 2019 Global Healthcare Conference
May 30, 2019 07:59 ET
|
Akorn, Inc.
LAKE FOREST, Ill., May 30, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019...
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
May 20, 2019 16:05 ET
|
Akorn, Inc.
LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
Akorn to Present at the RBC Capital Markets Healthcare Conference
May 20, 2019 08:01 ET
|
Akorn, Inc.
LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC...
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
May 07, 2019 07:05 ET
|
Akorn, Inc.
-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc....
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
April 18, 2019 17:00 ET
|
Akorn, Inc.
LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
April 18, 2019 16:05 ET
|
Akorn, Inc.
LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...